Document Detail

Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up.
MedLine Citation:
PMID:  23283524     Owner:  NLM     Status:  MEDLINE    
Plasma estrogen and androgen levels are positively associated with postmenopausal breast cancer risk, but how long a single blood measurement can predict risk and whether the associations vary by tumor hormone receptor status remain unclear. We conducted nested case-control analyses within the Nurses' Health Study. Blood samples were collected in 1989-1990 and again in 2000-2002. Among postmenopausal women not using postmenopausal hormones at blood collection, 707 cases were diagnosed through June 2010, with two matched controls per case. We used unconditional logistic regression analyses to estimate the relative risks controlling for other breast cancer risk factors. The intra-class correlation coefficients for two blood measurements collected 10 years apart ranged from 0.54 (dehydroepiandrosterone sulfate, DHEAS) to 0.74 (sex hormone-binding globulin, SHBG). Overall, women in the top (vs. bottom) 25 % of levels of estradiol, free estradiol, testosterone, free testosterone, and DHEAS were at a 50-110 % higher risk of breast cancer (p (trend) < 0.001). SHBG was inversely associated with risk (p (trend) = 0.004). RRs were similar when comparing cases diagnosed 1-10 versus 11-20 years (or 16-20 years) after blood collection (p (interaction) > 0.2). Except for DHEAS, the associations varied significantly by hormone receptor status (p (heterogeneity) ≤ 0.02). For example, the RRs (95 % CIs) comparing the highest versus lowest quartile were 2.8 (2.0-4.0; p (trend) < 0.001) for ER +/PR + tumors versus 1.1 (0.6-2.1; p (trend) = 0.98) for ER-/PR- tumors for estradiol, and 1.8 (1.3-2.5; p (trend) < 0.001) versus 0.6 (0.3-1.2; p (trend) = 0.35) for testosterone. One measure of circulating sex hormones in postmenopausal women can predict risk of hormone receptor positive breast cancer for up to 16-20 years.
Xuehong Zhang; Shelley S Tworoger; A Heather Eliassen; Susan E Hankinson
Related Documents :
22963114 - Venous thromboembolism risk in relation to use of different types of postmenopausal hor...
16353354 - Effect of ethnicity and geographical location on body weight, dietary restraint, and ab...
14622084 - Great expectations: "i'm losing 25% of my weight no matter what you say".
11920994 - The relationship of self-esteem and body esteem in women with and without eating disord...
20463224 - Neural processing of risk.
24750064 - Contribution of socio-economic status on the prevalence of cerebral palsy: a systematic...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-01-03
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  137     ISSN:  1573-7217     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-23     Completed Date:  2013-06-27     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  883-92     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Breast Neoplasms / blood*,  epidemiology*
Case-Control Studies
Follow-Up Studies
Gonadal Steroid Hormones / blood*
Middle Aged
Postmenopause / blood*
Grant Support
Reg. No./Substance:
0/Gonadal Steroid Hormones
Comment In:
Climacteric. 2013 Jun;16(3):401-2   [PMID:  23814882 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  2-Hydroxycinnamaldehyde inhibits the epithelial-mesenchymal transition in breast cancer cells.
Next Document:  Adjuvant chemotherapy reduces the incidence of abdominal hypertrophic scarring following immediate T...